Exosomal miRNA Biomarkers for Predicting PARP Inhibitor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments with PARP inhibitors face challenges in predicting therapeutic responsiveness and prognosis, leading to potential resistance and adverse effects, necessitating a method to identify suitable candidates for these therapies.
Innovation Solution
Measuring the expression levels of miR-664a-5p, miR-98-5p, and miR-95-3p in cancer patients and comparing them to control groups to predict responsiveness to PARP inhibitors, using agents like primers and probes, and administering miRNAs or overexpression agents to enhance sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitor therapy is administered to all cancer patients, then potential therapeutic benefits may be achieved, but treatment costs increase and adverse effects occur in patients who do not respond to therapy
Solution Approach 1:
The patent extracts specific miRNA molecules (miR-664a-5p, miR-98-5p, miR-95-3p) from complex biological systems as isolated biomarkers for PARP inhibitor responsiveness. By focusing on these specific extracted miRNAs rather than analyzing entire transcriptomes, the diagnostic method achieves high predictive accuracy while maintaining procedural simplicity through targeted measurement approaches
Solution Approach 2:
The patent introduces miRNA expression levels as intermediary biomarkers that mediate between patient characteristics and PARP inhibitor therapeutic response. These miRNA intermediaries provide measurable signals that predict treatment outcomes, enabling clinicians to identify responsive patients without directly observing complex therapeutic response mechanisms
2Measurement precision
If miRNA expression levels are measured to predict PARP inhibitor responsiveness, then treatment efficacy can be improved, but additional diagnostic steps and time are required
Solution Approach 1:
The patent performs preliminary identification and validation of specific miRNA biomarkers (miR-664a-5p, miR-98-5p, miR-95-3p) that are associated with PARP inhibitor responsiveness. By pre-establishing these specific miRNA targets and their predictive value, the actual clinical diagnostic process requires only measuring these predetermined markers, significantly reducing diagnostic time while maintaining high measurement precision
Solution Approach 2:
The patent focuses measurement efforts on specific local miRNA targets (miR-664a-5p, miR-98-5p, miR-95-3p) rather than performing comprehensive genomic analysis. This localized approach to measuring only the most predictive miRNAs achieves high measurement precision for treatment prediction while minimizing the time and resources required compared to broader genomic profiling
Data Source
AI summary
The present invention relates to a diagnostic biomarker composition for PARP inhibitor response and a pharmaceutical composition for cancer treatment, including at least one miRNA selected from the group consisting of exosomal miR-664a-5p, miR-98-5p, and miR-95-3p as an active ingredient. The biomarker of the present invention can predict the therapeutic responsiveness and prognosis of cancer patients to PARP inhibitors, enabling the early identification of patients in whom the efficacy of PARP inhibitors is limited due to the development of resistance. Additionally, it has been confirmed that the biomarker of the present invention directly targets FOXM1, a transcription factor involved in chemotherapy resistance, to enhance sensitivity to PARP inhibitors. This finding demonstrates that the differential expression of the biomarker of the present invention plays a crucial role in regulating the efficacy of PARP inhibitors. Furthermore, the biomarker of the present invention can be identified as a potential therapeutic target for PARP inhibitor response in cancer patients.Accordingly, the biomarker of the present invention, either alone or in combination with a PARP inhibitor, can be effectively utilized for the treatment, prevention, and improvement of cancer.